Expressive

rs10021804 - EGF - ELOVL6

Magnitude 2.2 · 1 study on file

Reported associations

  • Genome-wide association studies in a large Korean cohort identify quantitative trait loci for 36 traits and illuminate their genetic architectures - Unknown journal (n.d.) · Unknown authors · PubMed 40436827

    ABSTRACT: Genome-wide association studies (GWAS) have predominantly focused on European ancestry populations, limiting biological discoveries across diverse populations. Here we report GWAS findings from 153,950 individuals across 36 quantitative traits in the Korean Cancer Prevention Study-II (KCPS2) Biobank. We discovered 301 previously unreported genetic loci in KCPS2, including an association between thyroid-stimulating hormone and CD36. Meta-analysis with the Korean Genome and Epidemiology Study, Biobank Japan, Taiwan Biobank, and UK Biobank identified 4588 loci that were not significant in any contributing GWAS. We describe differences in genetic architectures across these East Asian and European samples. We also highlight East Asian specific associations, including a known pleiotrop

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Diet

  • Reduce saturated fat intake Moderate

    SNP affects ELOVL6-mediated fatty acid elongation; dietary saturated fat reduction is standard approach for LDL management in genetically susceptible individuals

    Aim for less than 7% of daily calories from saturated fat

Exercise

  • Aerobic exercise for LDL management Moderate

    Regular aerobic exercise reduces LDL cholesterol; particularly important for individuals genetically predisposed to elevated LDL

    Target 150 minutes per week of moderate-intensity aerobic activity

Screening

  • Lipid panel screening Moderate

    This SNP strongly associates with higher LDL cholesterol; screening confirms phenotypic expression of genetic risk

    Baseline lipid panel if not done within 1 year; then every 2-5 years